When a novel or highly lethal pathogen emerges, scientific progress faces an immediate physical bottleneck: the laboratory wall. Research on dangerous viruses and bacteria—such as SARS-CoV-2, poliovirus, West Nile virus, and Mycobacterium tuberculosis—is strictly confined to Biosafety Level 3 (BSL-3) or Level 4 (BSL-4) facilities.
As noted by Qiaoyu Li et al. and Guohua Li et al., these high-containment laboratories are scarce, expensive to operate, and heavily regulated. This infrastructure deficit creates a severe operational bottleneck. During a public health crisis, thousands of standard academic and industrial laboratories are effectively locked out from contributing to diagnostic development, vaccine validation, and high-throughput drug screening. Even when working within high-containment spaces, experimental scopes are frequently curtailed by safety protocols, as highlighted by Dongyao Wang et al..
To bypass these constraints, a powerful paradigm has emerged: engineering non-infectious biological surrogates. By decoupling the specific molecular mechanisms of interest (such as viral entry, replication, or enzymatic activity) from the capacity to cause disease or propagate, researchers can safely move high-consequence pathogen research into standard BSL-2 or benchtop environments.
Decoupling Entry from Replication: Pseudoviruses and VLPs
To measure how well a vaccine or an antibody neutralizes a virus, traditional assays require mixing the antibody with live virus and observing whether it infects a cell culture. This requires live, infectious pathogens.
Pseudotyped viruses and Virus-Like Particles (VLPs) solve this by separating the virus's "key" (its surface envelope or spike proteins) from its "engine" (the genetic code required to replicate and cause disease).
Live Pathogen: [ Dangerous Genome ] + [ Surface Spike ] ===> Replicates & Spreads
Pseudovirus/VLP: [ Reporter/No Genome ] + [ Surface Spike ] ===> Single Entry Only (Safe)
To build a pseudovirus, researchers take a benign viral backbone (such as a modified lentivirus or vesicular stomatitis virus) that has been stripped of its replication genes and engineered to carry a visible reporter gene, like luciferase or green fluorescent protein (GFP). They then force this backbone to express the surface envelope protein of the target pathogen.
When this surrogate interacts with a cell, it uses the target pathogen's entry mechanism. Once inside, however, it cannot replicate or escape; it simply switches on the reporter gene. If an antibody blocks the virus, the cell remains dark.
- Multi-Serotype Tracking: Meiyan Liu et al. developed a tri-color pseudovirus assay for poliovirus. By pairing different poliovirus serotype capsids with distinct fluorescent reporters, they could simultaneously track neutralization against three separate strains in a single safe, high-throughput BSL-2 well.
- Agricultural Applications: This approach extends to veterinary medicine. Haojie Wang et al. engineered a bioluminescent pseudovirus for Transmissible Gastroenteritis Virus (TGEV), allowing commercial swine laboratories to perform rapid antibody screening without handling live agricultural threats.
- Structural Mimicry: Going a step further, Liang Ma et al. designed "safe-by-design" virus-like particles for SARS-CoV-2. These particles mimic the structural morphology and host-interaction behavior of the native virus but contain absolutely no viral genetic material, making them completely incapable of replication.
Isolating Intracellular Machinery: Replicons and Chimeras
While pseudoviruses model how a virus gets into a cell, they cannot model what happens inside—such as genome replication and translation. To screen for antiviral drugs that halt replication, researchers traditionally needed live viruses. The surrogate solution to this is the replicon system.
A replicon is a self-replicating RNA molecule derived directly from the virus's genome, but with a critical modification: the genes encoding the structural proteins (the shell and envelope) are entirely deleted and replaced with a reporter gene.
When introduced into a cell, the replicon replicates its own RNA using the virus's native non-structural machinery, triggering the reporter signal. However, because it lacks structural genes, it cannot package itself into new viral particles. It is a biological dead-end.
- High-Throughput Screening: Yu-Qian Mao et al. utilized a BSL-2 compatible SARS-CoV-2 replicon system to safely screen small-molecule libraries, successfully identifying pan-coronavirus inhibitors that target host protein homeostasis.
- Rapid Assembly: To accelerate this process, Yuyuan Zhang et al. leveraged yeast-based Transformation-Associated Recombination (TAR) cloning to rapidly assemble coronavirus replicons and reporter viruses, drastically shortening the timeline required to set up sensitive antiviral screening platforms.
- Chimeric Backbones: Another variation involves swapping dangerous genes into safe, well-characterized vaccine strains. Guohua Li et al. engineered a chimeric West Nile Virus by placing its structural proteins onto a safe, attenuated Japanese Encephalitis Virus vaccine backbone, lowering the biosafety barrier for studying West Nile pathogenesis and vaccine candidates.
Eliminating the Cell: Cell-Free and In Vitro Reconstitution
The safest way to handle a pathogen's machinery is to remove the living cell entirely. By isolating specific biochemical pathways in a test tube, researchers eliminate any possibility of biological replication or accidental infection.
Cell-Based Assay: [ Live Cell + Pathogen ] ===> Requires Containment, Slow Growth
Cell-Free Assay: [ Purified Target Enzyme + Substrate ] ===> Benchtop Safe, Instant Readout
For instance, instead of monitoring how a virus infects a cell culture to test a drug, researchers can isolate the specific viral enzyme the drug is meant to block. Gangan Yan et al. developed a miniaturized fluorescence polarization assay focused exclusively on the SARS-CoV-2 main protease ($M^{pro}$). By watching the enzyme cleave a synthetic, fluorescently tagged substrate in a cell-free solution, they could rapidly identify potent inhibitors without ever culturing a live pathogen.
This cell-free philosophy also extends to complex molecular systems and diagnostics:
- Decoy-Driven Assays: Ji Youn Lim et al. bypassed live-virus neutralization tests entirely by engineering a cell-free assay that uses a "decoy" fusion protein. The decoy filters out non-specific antibodies, allowing a simple, benchtop chemical readout to accurately quantify true neutralizing antibodies.
- Bottom-Up Reconstitution: For slow-growing or dangerous bacteria, researchers can rebuild core metabolic pathways from scratch. Aashish Srivastava et al. successfully reconstituted the entire protein translation machinery of Mycobacterium in vitro using purified recombinant factors. This allowed them to study species-specific translation mechanics and antibiotic sensitivities without waiting for slow, hazardous bacterial growth cycles.
- Simplified Diagnostics: In the early days of the COVID-19 pandemic, Joungha Won et al. focused on simplifying molecular detection protocols, demonstrating that optimizing basic, low-cost laboratory steps could expand diagnostic capacity without relying on specialized, high-containment extraction infrastructure.
Benign Environmental Surrogates
In some scenarios, the research goal is not to study the biology of a pathogen, but to test physical countermeasures, such as disinfectants or air filtration systems. Even here, using live high-consequence pathogens is unnecessarily hazardous.
The solution is to identify a completely harmless organism that shares identical physical or structural characteristics with the dangerous pathogen. For example, Chae Hong Rhee et al. validated the use of Bacteriophage MS2—a virus that infects only bacteria and is entirely harmless to humans and animals—as a physical surrogate for Foot-and-Mouth Disease Virus (FMDV). Because MS2 shares a similar size, shape, and environmental resistance profile with FMDV, commercial manufacturers and local diagnostic labs can routinely validate biosecurity disinfectants on an open benchtop.
Summary
By shifting the analytical focus from the whole organism to engineered components—whether through pseudoviruses, replicons, cell-free biochemistry, or physical surrogates—the scientific community effectively democratizes pathogen research. These technologies convert high-containment logistical bottlenecks into scalable, high-throughput, and benchtop-safe workflows, accelerating the global development of diagnostics, therapeutics, and vaccines.
Key Foundational Work
Reconstitution of Protein Translation of Mycobacterium Reveals Functional Conservation and Divergence with the Gram-Negative Bacterium Escherichia coli (2016) — contributed 1 concept elements to this direction.
Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19) (2020) — contributed 1 concept elements to this direction.